公开(公告)号：US09242929B2

公开(公告)日：2016-01-26

申请号：US14118913

申请日：2012-05-18

申请人： Siegfried Benjamin Christensen, IV ,  Rowena Christensen ,  Donghui Qin ,  Hemant Joshi ,  Raghuram S. Tangirala

发明人： Siegfried Benjamin Christensen, IV ,  Donghui Qin ,  Hemant Joshi ,  Raghuram S. Tangirala

IPC分类号： C07C275/42 ,  C07D217/26 ,  C07D239/42 ,  C07D213/75 ,  C07D241/20 ,  C07D237/20 ,  A61K31/17 ,  A61K31/4418 ,  A61K31/444 ,  A61K31/472 ,  A61K31/4965

CPC分类号： C07C275/42 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10 ,  C07D213/75 ,  C07D217/24 ,  C07D217/26 ,  C07D237/20 ,  C07D239/42 ,  C07D241/20

摘要： This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.

公开(公告)号：US20150307445A1

公开(公告)日：2015-10-29

申请号：US14118913

申请日：2012-05-18

申请人： Rowena CHRISTENSEN

发明人： Siegfried Benjamin Christensen, IV ,  Donghui Qin ,  Hemant JOSHI ,  Raghuram S. Tangirala

IPC分类号： C07C275/42 ,  C07D237/20 ,  C07D213/75 ,  C07D241/20 ,  C07D217/26 ,  C07D239/42

CPC分类号： C07C275/42 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10 ,  C07D213/75 ,  C07D217/24 ,  C07D217/26 ,  C07D237/20 ,  C07D239/42 ,  C07D241/20

摘要： This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.

摘要翻译： 本发明涉及作为酰基辅酶A：二酰基甘油酰基转移酶1（DGAT-1）的抑制剂的新化合物，含有它们的药物组合物，其制备方法及其在治疗中用于预防或治疗与DGAT有关的疾病 -1功能障碍或DGAT-1活性的调节可能具有治疗益处，包括但不限于肥胖症，肥胖相关疾病，高甘油三酯血症，高脂蛋白血症，乳糜微粒血症，血脂异常，非酒精性脂肪性肝炎，糖尿病，胰岛素抵抗，代谢综合征，丙型肝炎病毒 感染和痤疮或其他皮肤疾病。